Wang, Zheyu
Luan, Jingyi
Seth, Anushree http://orcid.org/0000-0003-2995-2200
Liu, Lin
You, Minli
Gupta, Prashant
Rathi, Priya
Wang, Yixuan
Cao, Sisi
Jiang, Qisheng
Zhang, Xiao
Gupta, Rohit http://orcid.org/0000-0001-7570-7527
Zhou, Qingjun
Morrissey, Jeremiah J.
Scheller, Erica L. http://orcid.org/0000-0002-1551-3816
Rudra, Jai S. http://orcid.org/0000-0002-7837-4980
Singamaneni, Srikanth http://orcid.org/0000-0002-7203-2613
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R56DE027924, R01DE027098, R01DE027098)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R21DA036663)
National Science Foundation (CBET-1900277)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA141521, R21CA236652)
Article History
Received: 4 May 2020
Accepted: 4 December 2020
First Online: 22 January 2021
Competing interests
: The authors declare the following competing financial interests: J.L., J.J.M. and S.S. are inventors on a provisional patent related to plasmonic fluor technology and the technology has been licensed by the Office of Technology Management at Washington University in St Louis to Auragent Bioscience LLC, which is developing plasmonic fluor products. J.L., J.J.M. and S.S. are co-founders and shareholders of Auragent Bioscience LLC. These potential conflicts of interest have been disclosed and are being managed by Washington University in St Louis.
Free to read: This content has been made available to all.